drugset / Trial / NCT05602818

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

NCT05602818

Phase 1 Completed 100 enrolled Takeda
RandomizedCrossoverDouble-blindOther

Summary

The main aim is to evaluate the relative abuse potential of soticlestat in healthy adults who has used central nervous system (CNS) depressants for recreational nontherapeutic reasons.

Timeline

Start
2022-11-15
Primary completion
2023-06-29
Completion
2023-07-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 2 mg Oral
Subject Soticlestat Small molecule 300 mg Oral
Subject Soticlestat Small molecule 600 mg Oral
Subject Soticlestat Small molecule 900 mg Oral

Indications

No indication recorded.